• Avaí Bio’s joint venture Insulinova entered a research and option agreement with San Raffaele Hospital in Milan on encapsulated cell therapy.
• Program targets Type 1 diabetes, insulin-dependent Type 2 diabetes using stem cell-derived beta cells combined with Austrianova’s Cell-in-a-Box encapsulation.
• Insulinova will fund the research, supply encapsulation equipment, materials, technical support toward potential commercialization of beta cell replacement therapy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avai Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608120830PRIMZONEFULLFEED9808482) on August 12, 2026, and is solely responsible for the information contained therein.